Endovascular aneurysm sealing system linked with low rate of endoleak at 1 year

New data from the EVAS FORWARD Global Registry demonstrate low rates of endoleak, reintervention and mortality at 1 year among patients with abdominal aortic aneurysm treated with an endovascular aneurysm sealing system.

The registry included 300 patients with AAA enrolled from October 2013 to September 2014 who were treated with the Nellix EndoVascular Aneurysm Sealing System (Endologix) at centers in Europe and New Zealand. Thirty-three patients had complex AAA anatomies. Mean follow-up was 14 months, according to a press release.

At 1 year, the rate of aneurysm-related mortality was 0.4% and overall survival was 95%. In total, 5.9% of patients experienced major adverse events. Endoleak occurred in 0.7% of patients at 1 year, and the rate of reintervention for limb occlusion was 1%, according to the release. The data were presented at the VEITHsymposium in New York.

“The data from the Nellix EVAS Forward Global Registry continue to show promise for EVAS to become a leading therapy in the treatment of patients with AAA,” Andrew Holden, MD, associate professor of radiology at Auckland City Hospital in Auckland, New Zealand, stated in the release. “The 0.7% endoleak incidence at 1 year represents the lowest overall rate ever reported for any commercially available endovascular device treating AAA.”

The Nellix system is designed to seal the entire aneurysm sac. It was developed to reduce all types of endoleaks, improve stability and long-term patient outcomes. The system is approved for investigational use only in the United States.

Reference:

Holden A, de Vries JP. Nellix Endograft System for EVAS: Key Points from the Global Registry and How to Prevent, Diagnose and Treat Type IA Endoleaks. Presented at: VEITHsymposium; Nov. 17-21, 2015; New York.

Disclosure: Cardiology Today’s Intervention could not confirm relevant financial disclosures.